Please assess the completion status of the following clinical trial:

Trial Title: Tepilta® Versus Oxetacaine, Antacids and Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female ≥ 18 years.~2. Score = 0 on NRS for oesophageal pain.~3. Radiotherapy (RT) or combined radio-chemotherapy (RCT) of a solid tumour in head/neck/thorax region. A minimum length of 5 cm of the oesophagus must be included in high-dose radiation field.~4. Duration of RT 5 to 8 weeks.~5. Single radiation dosage of fractionated RT 1.8 to 2.0 Gy/day, of intensity-modulated RT (IMRT) 1.5 to 2.3 Gy/day, each for 5 days a week (single frequency deviations are allowed presuming that intended duration of RT remains 5 to 8 weeks).~6. First radiation in the intended radiation area.~7. Written informed consent.~   Randomisation criteria:~8. Appearance of oesophageal pain as follows: Score ≥ 2 on Numeric Rating Scale (NRS) for pain during main daily meals is reached at least once.~9. At least 20 Gy of the dose of radiation therapy in oesophageal area remaining.~10. Oesophageal symptoms of grade ≤ 2a according to the adapted Common Terminology Criteria for Adverse Events CTCAE.~Exclusion Criteria:~1. History of allergic reaction to the study medication or its excipients (i.e. aluminium or magnesium hydroxide, oxetacaine, any other ingredient of study medication).~2. Pregnancy, breast-feeding or planned pregnancy during the study.~3. Known hypermagnesaemia.~4. Known hypophosphataemia.~5. Clinically significant obstipation, as judged by the investigator.~6. Acute appendicitis.~7. Total intended radiation dose at lips and the anterior oral cavity \> 60% of total intended radiation dose at the swallowing process (pharynx, oesophagus).~8. Hyper-fractionated RT.~9. Intended naso-gastral tubes.~10. Primary tumour of the cranial base, brain, oral cavity, lips, naso-pharynx, para-nasal sinuses.~11. Known bone metastases.~12. Reflux oesophagitis 3 months prior to the study.~13. Continuous systemic pain treatment at the beginning of RT. Systemic pain medication for oesophagitis prior to randomisation must not be taken.~14. Concomitant treatment with tetracyclines, cinolone derivatives (ciprofloxacin, ofloxacin, enoxacin, norfloxacin), cheno-desoxycholic acid, sodium fluoride, local anaesthetics (other than those used as study medication).~15. Patients relying on levothyroxine after resection of thyroid carcinoma being hypothyroid and patients relying on levothyroxine due to other reasons not being euthyroid.~16. Artificial nutrition at the beginning of radiation.~17. Drug (licit and illicit) or alcohol abuse which would interfere with the patient's proper completion of the study.~18. Exposure to an investigational product within the last 4 weeks, simultaneous exposure to another investigational product.~19. Lack of ability or willingness to give informed consent.~20. Anticipated non-availability for study visits / procedures.~21. Lack of ability or willingness to keep patient's diary.~22. Lack of willingness to have personal study related data collected, archived or transmitted according to the protocol.~23. Vulnerable subjects.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tepilta® (Type: EXPERIMENTAL): None
- Oxetacaine (Type: ACTIVE_COMPARATOR): None
- Antacids (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).